ICCC IMMUCELL CORP /DE/ Insider Trading

ICCC CEO Te Boekhorst buys 8,000 shares at $9.50; holdings surge 81.8% to 17.8K; cross-ticker track record shows 100% 90d win rate.

Boekhorst Paul Francis Olivier Te, President and CEO, purchased 8,000 shares at $9.50 on 2026-06-18, increasing his holdings by 81.8% from 9,785 to 17,785 shares. His cross-ticker track record across all open-market buys shows an average 90-day return of +29.7% with a 90d win rate of 100.00%, and his prior three trades at ICCC specifically (2025-12-03 and 2025-12-02) each posted 90-day gains of 27.9%, 27.0%, and 34.3% respectively. The current stock price of $9.49 sits 11.7% below the 52-week high of $10.75 and reflects a 90-day gain of +56.3%, though the most recent 30-day period shows -7.0% decline. The purchase occurs as the company reported quarterly net income of $1,941,607.00 against revenue of $10,357,295.00, though the company was unprofitable over its most recent full fiscal year.

CEO Paul Francis Olivier Boekhorst buys 9,785 shares at blended average $4.97, stock now $5.25 down 30.9% from 52-week high.

Paul Francis Olivier te Boekhorst, the company's President and CEO, executed 3 separate purchases totaling 9,785 shares for $48,588.39 at a blended average price of $4.97, with no prior shareholding. This represents a material open-market equity stake acquisition by the top executive at IMMUCELL CORP. The purchases occurred on 2025-12-02 and 2025-12-03 as the stock traded in the $4.87–$5.04 range, against a current price of $5.25 and a 52-week range of $4.12–$7.60. Despite positive fundamentals—annual revenue growth of 51.6% and quarterly revenue of $5,506,122.00—the company remains unprofitable (net income of $-139,748.00 most recently), and the stock is down 30.9% from its 52-week high and 15.5% over 30 days. The CEO's decision to accumulate a first-time stake at depressed levels during a period of negative recent momentum warrants investor review of the underlying business trajectory and the strategic rationale for this acquisition timing.

Director David Scott Tomsche buys 3,266 shares at $4.76 in 2 transactions, increasing stake +221.6% to 4,740 shares as stock down 24.4% in 90 days.

Director David Scott Tomsche executed 2 separate purchases totaling 3,266 shares for $15,554.33 at a blended average price of $4.76 on 2025-11-25, more than tripling his pre-transaction holdings from 1,474 shares to 4,740 shares. The transaction occurred against a backdrop of recent stock weakness: the current price of $4.84 is 36.3% below the 52-week high of $7.60, and the stock has declined 24.4% over the past 90 days and 19.7% over the past 30 days. The company is unprofitable on a full-year basis (net income was negative), though it reported 51.6% annual revenue growth and generated $5.5M in latest quarterly revenue; market capitalization stands at $43.8M. The significant increase in holdings following substantial recent price declines warrants assessment of whether this reflects management confidence in recovery or other motivations.

Director Gathagan purchases 1,000 shares of ICCC at $6.32; company showed +51.6% revenue growth but remains unprofitable on annual basis

Director Bryan K. Gathagan initiated a position in IMMUCELL CORP /DE/ with a purchase of 1,000 shares at $6.32, moving from zero prior holdings. The purchase arrives during a period of significant positive momentum: the stock has appreciated 28.8% over the past 30 days and 28.5% over the past 90 days. The company's fundamentals show strong revenue expansion of $8,067,174.00 in the latest quarter and annual revenue growth of +51.6%, though ICCC reported negative full-year net income despite posting $1,446,983.00 in most recent quarterly net income. The timing of this director purchase against a backdrop of strong operational growth but persistent annual losses, combined with recent stock momentum, merits investor attention to understand whether this trade reflects conviction in the turnaround narrative or reflects other motivations.